In English | En español
Questions About Cancer? 1-800-4-CANCER

Clinical Trials Search Results

View Content for:
Display:
  •          
Help with display options.
Results 1-25 of 292 for your search:
Cancer Type/Condition:  Multiple myeloma / Plasma cell neoplasm
Stage/Subtype:  multiple myeloma
Country:  U.S.A.
Trial Type:  Treatment
Trial Status:  Active
Start Over
        Show
1.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CC-5013-MM-016, FHCRC-2068.00, CELGENE-CC-5013-MM-016, NCT00179647
2.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: UPCI 07-134, NCT00777881
3.

Phase: Phase IV
Type: Health services research, Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: Plerixafor-UF01, NCT01339572
4.

Phase: Phase IV
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: AAAJ2355, NCT01731886
5.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: UARK 2003-26, NCT00090493
6.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 19 to 70
Sponsor: Other
Protocol IDs: F080429003, UAB-0775, NCT00714259
7.

Phase: Phase III, Phase II
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: 2004LS001, MT2003-13, 0312M54569, UMN-2004LS001, UMN-MT2003-13, UMN-0312M54569, NCT00293306, NCT00177047
8.

Phase: Phase III, Phase II
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: Any Age
Sponsor: Pharmaceutical / Industry
Protocol IDs: CDX-353-002, NCT01660633
9.

Phase: Phase III
Type: Treatment
Status: Active
Age: 54 and under
Sponsor: Other
Protocol IDs: 0107M05202, MT2001-02, NCT00176930
10.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2009-00798, S0777, U10CA032102, CDR0000590321, SWOG-S0777, NCT00644228
11.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: UARK 2008-01, NCT00734877
12.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: APL-C-001-09, NCT01102426
13.

Phase: Phase III
Type: Treatment
Status: Active
Age: 70 and under
Sponsor: NCI, NHLBI
Protocol IDs: 690, NCT01109004
14.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Other
Protocol IDs: 1005011049, X05324, NCT01146834
15.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Treatment
Status: Active
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-2011-02057, E3A06, ECOG-E3A06, CDR0000682012, U10CA021115, NCT01169337
16.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 65
Sponsor: Other
Protocol IDs: 10-106, NCT01208662
17.

Phase: Phase III
Type: Biomarker/Laboratory analysis, Supportive care, Treatment
Status: Active
Age: not specified
Sponsor: NCI, Other
Protocol IDs: 2448.00, NCI-2010-02035, P01CA018029, NCT01231412
18.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 75
Sponsor: Other
Protocol IDs: Pro00001295, NCT01241708
19.

Phase: Phase III
Type: Treatment
Status: Active
Age: 19 and over
Sponsor: NCI, Other
Protocol IDs: CASE3A10, NCI-2011-00186, NCT01301963
20.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: CA204-006, 2010-022445-20, NCT01335399
21.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 20090482, NCT01345019
22.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 to 70
Sponsor: Other
Protocol IDs: 2010-0071, NCT01413178
23.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: AB06002, NCT01470131
24.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: C16010, 2011-005496-17, NCT01564537
25.

Phase: Phase III
Type: Treatment
Status: Active
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: 2011-003, 2012-000128-16, NCT01568866
1     
New Search